Assessing the safety of inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents

By | June 30, 2021
New clinical trial data, recently published in The Lancet’s Infectious Diseases, presents an initial report on the effect of an inactivated SARS-CoV-2 vaccine, CoronaVac, on children and adolescents from ages 3-17 in a double-blind, randomized setting.